VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies

At a glance

Company: VERAXA Biotech
Ticker: NASDAQ: VRXA
Announcement: Product

Key figures

Granted owned or exclusively licensed patents: more than 50
Patent families: 26
Countries with patent coverage: 14
Expected protection through: at least 2047

Products and programs

VXA-222
BiTAC platform
Bispecific antibody-drug conjugates
T-cell engagers
Engineered antibody formats

The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage of development following completion of the discovery phase with OmniAb.
OmniAb delivered a portfolio of therapeutic antibody binders, with VERAXA now responsible for engineering the final bispecific ADC candidate and advancing preclinical validation.
Although VXA-222 is not based on VERAXA’s BiTAC platform, it leverages the company’s proprietary antibody engineering, linker and conjugation technologies and represents one of its more advanced development programs.
VERAXA recently expanded its intellectual property portfolio with its first BiTAC-related patent filings alongside additional patents supporting conjugation chemistry, payloads and antibody technologies.
The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047.
VERAXA continues building a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.

VERAXA (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline, announcing that its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program has advanced beyond the discovery phase and into the next stage of development. The milestone reflects continued progress across the company’s therapeutic portfolio as it simultaneously expands the intellectual property supporting its next generation of antibody-based cancer therapies.

The announcement marks the successful completion of the discovery portion of VERAXA’s collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work completed, VERAXA will now focus on building the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own…

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

In brief

VERAXA Biotech says its VXA-222 bispecific antibody-drug conjugate program has moved beyond discovery after completion of that phase of its collaboration with OmniAb. VERAXA will now engineer the final candidate and conduct preclinical validation, using antibody binders delivered through the collaboration alongside its own engineering and conjugation technologies. The company also reported new patent filings covering BiTAC-related inventions, conjugation chemistry, payloads and antibody technologies. VERAXA says its portfolio includes more than 50 granted patents that it owns or exclusively licenses, across 26 patent families and 14 countries. Newly filed applications are expected by the company to extend protection into at least 2047. Its oncology pipeline includes bispecific ADCs, T-cell engagers and engineered antibody formats.

Key takeaways

VERAXA says VXA-222 has completed discovery and is moving into candidate engineering and preclinical validation.
The discovery phase of the company’s collaboration with OmniAb is complete.
New filings address BiTAC-related inventions and other antibody and conjugation technologies.
VERAXA reports more than 50 granted patents across 26 families in 14 countries.

SEC filings

Earlier from VERAXA Biotech

Back to News Center